Sach Pharmatech Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 24-06-2024
- Paid Up Capital ₹ 3.63 M
as on 24-06-2024
- Company Age 20 Year, 22 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.00 M
as on 24-06-2024
- Revenue 5.26%
(FY 2021)
- Profit 5.94%
(FY 2021)
- Ebitda -232.28%
(FY 2021)
- Net Worth 2.64%
(FY 2021)
- Total Assets 32.32%
(FY 2021)
About Sach Pharmatech
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 3.63 M.
The company currently has active open charges totaling ₹2.00 M.
Abhishek Arora and Om Arora serve as directors at the Company.
- CIN/LLPIN
U24232DL2004PTC130907
- Company No.
130907
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
01 Dec 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
North Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sach Pharmatech Private Limited offer?
Sach Pharmatech Private Limited offers a wide range of products and services, including Dentist Tools, Equipment & Supplies, Dental Equipment, Surgical & ICU Equipments, Electromedical Equipment, Hospital and Medical Furniture, Hospital Chair, Optical, Laser Instruments & Devices, Laser Instruments, Examination Lights, Surgical Light.
Who are the key members and board of directors at Sach Pharmatech?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Om Arora  | Managing Director | 02-Dec-2004 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Abhishek Arora | Director | 20-Apr-2015 | Current |
Financial Performance of Sach Pharmatech.
Sach Pharmatech Private Limited, for the financial year ended 2021, experienced modest growth in revenue, with a 5.26% increase. The company also saw a slight improvement in profitability, with a 5.94% increase in profit. The company's net worth moved up by a moderate rise of 2.64%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sach Pharmatech?
In 2021, Sach Pharmatech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 22 Sep 2021 | ₹2.00 M | Open |
How Many Employees Work at Sach Pharmatech?
Unlock and access historical data on people associated with Sach Pharmatech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sach Pharmatech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sach Pharmatech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
